pharma · hidradenitis suppurativa (HS) · Hidradenitis Suppurativa · MLTX
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Dorfstrasse, 29, Zug 6300, CH
- Founded
- 2021
- Employees
- 133
- Programs
- 13
- Drugs
- 11
- Patents
- 0
MoonLake Immunotherapeutics projects
4 ClinicalTrials.gov programs sponsored by MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
68Ga-FAPI-46, Sonelokimab
MoonLake Immunotherapeutics
psoriatic arthritis, axial spondyloarthritis
1 trial -
Sonelokimab
MoonLake Immunotherapeutics
axial spondyloarthritis
1 trial -
Sonelokimab
MoonLake Immunotherapeutics
Palmoplantar Pustulosis
1 trial -
Sonelokimab (M1095)
MoonLake Immunotherapeutics
Hidradenitis Suppurativa
1 trial
Frequently asked questions
How many clinical projects does MoonLake Immunotherapeutics have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.